oru.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Intradermal HIV-1 DNA immunization using needle-free ZetajetTM injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial
Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique.
Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique.
Division of Clinical Microbiology, Department of Laboratory Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Public Health Agency of Sweden (Folkhälsomyndigheten), Stockholm, Sweden.
Instituto Nacional de Saúde, Maputo, Mozambique.
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: AIDS Research and Human Retroviruses, ISSN 0889-2229, E-ISSN 1931-8405, Vol. 34, nr 2, s. 193-205Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

We assessed safety and immunogenicity of HIV-DNA priming using Zetajet<sup>TM</sup>, a needle-free device intradermally followed by intramuscular HIV-MVA boosts, in 24 healthy Mozambicans. Volunteers were randomized to receive three immunizations of 600 µg (n = 10; 2 x 0.1mL) or 1200 µg (n = 10; 2 x 0.2mL) of HIV-DNA (3 mg/mL), followed by two boosts of 10<sup>8</sup>pfu HIV-MVA. Four subjects received placebo saline injections. Vaccines and injections were safe and well tolerated with no difference between the two priming groups. After three HIV-DNA immunizations, IFN-γ ELISpot responses to Gag were detected in 9/17 (53%) vaccinees, while none responded to Env. After the first HIV-MVA, the overall response rate to Gag and/or Env increased to 14/15 (93%); 14/15 (93%) to Gag and 13/15 (87%) to Env. There were no significant differences between the immunization groups in frequency of response to Gag and Env or magnitude of Gag responses. Env responses were significantly higher in the higher-dose group (median 420 vs 157.5 SFC/million PBMC, p=0.014). HIV-specific antibodies to subtype C gp140 and subtype B gp160 were elicited in all vaccinees after the second HIV-MVA, without differences in titers between the groups. Neutralizing antibody responses were not detected. Two (13%) of 16 vaccinees, one in each of the priming groups, exhibited antibodies mediating antibody-dependent cellular cytotoxicity to CRF01_AE. In conclusion, HIV-DNA vaccine delivered intradermally in volumes of 0.1-0.2 mL using Zetajet<sup>TM</sup> was safe and well tolerated. Priming with the 1200 µg dose of HIV-DNA generated higher magnitudes of ELISpot responses to Env.

Ort, förlag, år, upplaga, sidor
Mary Ann Liebert, 2018. Vol. 34, nr 2, s. 193-205
Nyckelord [en]
HIV, vaccine, Mozambique, HIV-DNA, HIV-MVA
Nationell ämneskategori
Infektionsmedicin Immunologi inom det medicinska området
Identifikatorer
URN: urn:nbn:se:oru:diva-61451DOI: 10.1089/AID.2017.0121ISI: 000417253800001PubMedID: 28969431Scopus ID: 2-s2.0-85041709186OAI: oai:DiVA.org:oru-61451DiVA, id: diva2:1150575
Anmärkning

Funding Agencies:

NIH  AI064518 

European and Developing Countries Clinical Trials Partnership  CT.200633111.007 

Regional HIV/AIDS Team for Africa, Embassy of Sweden, Lusaka  

Sida  2150012801 

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.  W81XWH-07-2-0067  W81XWH-11-0174 

U.S. Department of Defense (DOD)  

U.S. National Institutes of Health  NCT01407497 

Pan African Clinical Trials Registry  PACTR201106000304583 

Tillgänglig från: 2017-10-19 Skapad: 2017-10-19 Senast uppdaterad: 2018-09-14Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Andersson, Sören

Sök vidare i DiVA

Av författaren/redaktören
Andersson, Sören
Av organisationen
Institutionen för medicinska vetenskaper
I samma tidskrift
AIDS Research and Human Retroviruses
InfektionsmedicinImmunologi inom det medicinska området

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 234 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf